Company registration number 14584446 (England and Wales)
Graviton Bioscience Limited
Financial Statements
For the period ended
31 December 2023
Pages for filing with registrar
Graviton Bioscience Limited
Contents
Page
Company information
1
Statement of financial position
2
Statement of changes in equity
3
Notes to the financial statements
4 - 5
Graviton Bioscience Limited
Company Information
- 1 -
Director
S. Shamim
Company number
14584446
Registered office
Dixcart House
Addlestone Road
Bourne Business Park
Addlestone
Surrey
KT15 2LE
Accountants
Dixcart International Limited
Chartered Accountants
Dixcart House
Addlestone Road
Bourne Business Park
Addlestone
Surrey
KT15 2LE
Graviton Bioscience Limited
Statement Of Financial Position
As at 31 December 2023
31 December 2023
- 2 -
2023
Notes
£
£
Current assets
Debtors
4
20,037
Cash at bank and in hand
33,958
53,995
Creditors: amounts falling due within one year
5
(34,859)
Net current assets
19,136
Capital and reserves
Called up share capital
100
Profit and loss reserves
19,036
Total equity
19,136
The notes on pages 4 to 5 form part of these financial statements.
For the financial period ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The director of the company has elected not to include a copy of the income statement within the financial statements.true
The financial statements were approved and signed by the director and authorised for issue on 24 February 2025
S. Shamim
Director
Company registration number 14584446 (England and Wales)
Graviton Bioscience Limited
Statement Of Changes In Equity
For the period ended 31 December 2023
- 3 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 11 January 2023
-
Period ended 31 December 2023:
Profit and total comprehensive income
-
19,036
19,036
Issue of share capital
100
-
100
Balance at 31 December 2023
100
19,036
19,136
The notes on pages 4 to 5 form part of these financial statements.
Graviton Bioscience Limited
Notes To The Financial Statements
For the period ended 31 December 2023
- 4 -
1
General information
Graviton Bioscience Limited is a private company limited by shares incorporated in England and Wales. The registered office is Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE.
2
Accounting policies
2.1
Reporting period
The financial statements present information for the period from incorporation on 11 January 2023 to 31 December 2023.
2.2
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
2.3
Going concern
Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.
2.4
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for clinical trial support services provided in the normal course of business.
2.5
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.
2.6
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.
Basic financial liabilities
Basic financial liabilities are initially recognised at transaction and are subsequently carried at amortised cost, using the effective interest rate method. Financial liabilities classified as payable within one year are not amortised.
Graviton Bioscience Limited
Notes To The Financial Statements (Continued)
For the period ended 31 December 2023
2
Accounting policies
(Continued)
- 5 -
2.7
Taxation
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
2.8
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense.
2.9
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
3
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2023
Number
Total
1
4
Debtors
2023
Amounts falling due within one year:
£
Trade debtors
19,937
Other debtors
100
20,037
5
Creditors: amounts falling due within one year
2023
£
Trade creditors
658
Corporation tax
6,290
Other taxation and social security
21,122
Other creditors
6,789
34,859